Precigen (PGEN) Return on Capital Employed (2013 - 2026)
Precigen (PGEN) reported Return on Capital Employed of 74.55% for Q1 2026, up 4330.0% year-over-year from 1.68% in Q1 2025, and up 14.94% quarter-over-quarter from 87.65% in Q4 2025.
Precigen (PGEN) Return on Capital Employed (2013 - 2026) Analysis & Trends
Precigen (PGEN) has 14 years of Return on Capital Employed data on file, last reported at 74.55% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 74.55%, up 4330.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 74.55% (up 4330.0% YoY), and the FY2025 annual result was 97.73%, up 890.0% from the prior year.
- Return on Capital Employed improved to 74.55% in Q1 2026 per PGEN's latest filing, from 87.65% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 28.49% in Q1 2022 and troughed at 246.47% in Q3 2024.
- A 5-year average of 88.61% and a median of 74.55% in 2026 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed slumped 19393 bps in 2024, then soared 13418 bps in 2025.
- A 5-year view of Return on Capital Employed shows it stood at 47.64% in 2022, then plunged by 42 bps to 67.46% in 2023, then tumbled by 116 bps to 145.42% in 2024, then jumped by 40 bps to 87.65% in 2025, then grew by 15 bps to 74.55% in 2026.
- Business Quant data shows PGEN's Return on Capital Employed at 74.55% in Q1 2026, 87.65% in Q4 2025, and 112.29% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -107.40% |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -50.43% |
| 10 | Precigen | 1.27 Bn | 1.27 Bn | 20.69 Mn | -74.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.55% |
| Dec 31, 2025 | -87.65% |
| Sep 30, 2025 | -112.29% |
| Jun 30, 2025 | -113.01% |
| Mar 31, 2025 | -117.85% |
| Dec 31, 2024 | -145.42% |
| Sep 30, 2024 | -246.47% |
| Jun 30, 2024 | -173.39% |
| Mar 31, 2024 | -88.19% |
| Dec 31, 2023 | -67.46% |
| Sep 30, 2023 | -52.54% |
| Jun 30, 2023 | -38.20% |
| Mar 31, 2023 | -42.33% |
| Dec 31, 2022 | -47.64% |
| Sep 30, 2022 | -40.89% |
| Jun 30, 2022 | -30.06% |
| Mar 31, 2022 | -28.49% |
| Dec 31, 2021 | -26.16% |
| Sep 30, 2021 | -27.89% |
| Jun 30, 2021 | -27.15% |